THC Global Group Limited advised that the company has signed a Supply Agreement with MGC Pharmaceuticals Ltd. Under the Agreement, MGC Pharma will provide the Company with an immediate supplementary source of medicinal cannabis products, which will be packaged and made available to patients under the Canndeo brand. The Company expects to launch these products in Australia and New Zealand through first quarter of 2020. The Agreement also provides for MGC Pharma and THC Global to collaborate on the future supply of Active Pharmaceutical Ingredients (API) extracts as well as other finished product, including from THC Global's Southport Facility.

Accessing an immediate supplementary source of medicinal cannabis products, enables the Company to scale up its supply to patients quicker, and offer patients a broader initial product range under the Canndeo brand. The Agreement with MGC Pharma also provides the Company with access to Tetrahydrocannabinol containing formulations complementing the Company's current focus on producing Cannabidiol (CBD) extracts and increasing flexibility to offer new formulations of products. As THC Global scales up production at its Southport Facility - the Company will transition its Canndeo formulations to using its own Australian produced cannabis.

The Southport Facility also presents opportunities for future further collaboration between MGC Pharma and THC Global which will be considered on a bi-annual basis.